Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
$0.91+6.65%
报价 2026-11-06
市值
$1.8M
EV
$-2.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -96.7%
$0.38$27.40
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CRISCuris, Inc. | $1.8M | +6.6% | -84.3% | 99.3% | – | – | – | |
| PALIPalisade Bio, Inc. | $196.9M | -2.6% | +130.6% | 0% | – | – | – | |
| BCTXBriaCell Therapeutics Corp. | $34.5M | +20.8% | – | 0% | – | – | – | |
| CTXRCitius Pharmaceuticals, Inc. | $15M | -2.2% | +83.7% | 20% | – | – | – | |
| PCSAProcessa Pharmaceuticals, Inc. | $5.4M | +4.9% | -32.9% | 0% | – | – | – | |
| ICUSeaStar Medical Holding Corporation | $5.3M | -2.1% | +90.0% | 92.6% | – | – | – | |
| ASBPAspire Biopharma Holdings, Inc. | $933,359 | +19.7% | – | 18.4% | – | – | – | |
| 同行中位数 | – | – | +86.8% | 9.2% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。